The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global


MediciNova Receives Notice of Allowance for New Patent

04-Feb-2015 | Source : AG-IP News | Visits : 6104
LA JOLLA, Calif. - MediciNova Inc., a biopharmaceutical company announced in a press release that it has received a Notice of Allowance from the US Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of NASH (nonalcoholic steatohepatitis).

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier thanDecember 2032. The allowed claims cover a method of treating NASH, a method of reducing liver inflammation in NASH, a method of reducing hepatic fibrosis in NASH, and a method of reducing damage to liver cells in NASH using MN-001 or MN-002. The allowed claims cover oral administration, including tablets and capsules, as well as liquid dosage forms.

"We are very pleased that this new patent will be granted, and we will now have three different patents that cover MN-001 for the treatment of liver diseases," commented Yuichi Iwaki, MD, PhD, President and CEO ofMediciNova, Inc.

Related Articles